• Buffer Optimization Stabilizes RNA LNPs for Nebulized Delive

  2026-05-23

  This study presents a generalizable buffer-based approach to stabilize RNA-loaded lipid nanoparticles (LNPs) during nebulization, a key challenge for pulmonary RNA therapeutics. By systematically evaluating buffer composition, the authors demonstrate improved RNA retention, particle integrity, and bioactivity, laying the groundwork for efficient inhalable mRNA and siRNA therapies.

• Macrophage-Targeted mRNA-LNPs Enhance SCI Recovery in Mice

  2026-05-22

  Fu et al. demonstrate that macrophage-targeted delivery of Mms6 mRNA via lipid nanoparticles significantly promotes locomotor recovery after traumatic spinal cord injury (SCI) in mice. By enabling endogenous macrophages to resist ferroptosis and enhance repair, this strategy offers a promising therapeutic direction for SCI and highlights advances in targeted mRNA delivery technologies.

• Lyso-Tracker Red: Precision Lysosome Labeling in Live Cells

  2026-05-22

  Lyso-Tracker Red (SKU B8814) from APExBIO enables high-specificity, live-cell lysosome labeling, facilitating advanced workflows in immunology, oncology, and nanovaccine research. Its robust fluorescence, superior selectivity, and protocol flexibility empower researchers to resolve lysosomal dynamics with clarity that legacy dyes cannot match.

• ZCL278: Selective Cdc42 Inhibitor for Cell Motility & Fibros

  2026-05-21

  ZCL278 stands out as a selective Cdc42 inhibitor, enabling researchers to dissect cell motility, neuronal branching, and fibrosis pathways with high specificity. This guide details experimental workflows, troubleshooting strategies, and the practical impact of targeting Cdc42 signaling in advanced disease models.

• Polymeric Vectors for Stable and Efficient mRNA Delivery: Th

  2026-05-21

  Shi et al. introduce a rational '4Q' design framework for polymeric mRNA delivery vectors, optimizing for room-temperature storage, in vivo stability, and efficient release. Their new polycatechol vector demonstrates superior mRNA delivery and fluorescence expression, offering a significant advance for gene expression and imaging studies.

• Thermal Shift Assays for Ligand Identification in Bacterial

  2026-05-20

  This review highlights how thermal shift assays enable systematic identification of ligands for bacterial sensor proteins, clarifying mechanisms of microbial signaling. The approach's reliability, limitations, and methodological best practices are discussed, supporting its adoption in pathway analysis and drug discovery.

• Doxorubicin: Mechanism, Benchmarks, and Modern Research Use

  2026-05-20

  Doxorubicin (Adriamycin) is a validated DNA topoisomerase II inhibitor used as a chemotherapeutic agent for solid tumors and hematologic malignancies. Its mechanism centers on DNA intercalation, leading to apoptosis induction in cancer cells. This article presents atomic, evidence-backed facts and protocol parameters for research applications.

• HMGB1 Identified as Early Serum Biomarker in Diabetic Nephro

  2026-05-19

  This study used quantitative proteomics and network analyses to identify HMGB1 as a promising early serum biomarker for diabetic nephropathy (DN), addressing the limitations of current diagnostics. The findings pave the way for more sensitive, noninvasive monitoring approaches in DN clinical research.

• pH-Responsive i-Motif ASO Prodrugs for MYCN-Driven Tumors

  2026-05-19

  This study introduces a rationally designed, pH-responsive hairpin antisense oligonucleotide (ASO) prodrug system utilizing the i-motif for controlled release and selective antitumor activity in MYCN-amplified cells. The work demonstrates how structural tuning of ASO prodrugs can optimize both stability and release kinetics, providing a promising strategy for next-generation nucleic acid therapeutics.

• Cdc42 Inhibition as a Strategy Against Kidney Fibrosis Progr

  2026-05-18

  This study uncovers how targeting Cdc42, a Rho family GTPase, with a natural small molecule disrupts the GSK-3β/β-catenin pathway to mitigate kidney fibrosis. The work establishes Cdc42 as a direct molecular target in chronic kidney disease, suggesting new experimental avenues for anti-fibrotic intervention.

• Atorvastatin in Cholesterol Metabolism and Ferroptosis Resea

  2026-05-18

  Atorvastatin, a potent HMG-CoA reductase inhibitor, is enabling novel approaches in both cholesterol metabolism and ferroptosis-driven cancer research. This article delivers actionable protocols, troubleshooting guidance, and evidence-based insights for maximizing the value of APExBIO's Atorvastatin in cardiovascular and hepatocellular carcinoma models.

• 3D Collagen Microtissues: Advancing In Vitro Cancer Modeling

  2026-05-17

  This study presents a modular tissue engineering approach to create 3D collagen-based microtissues that closely replicate key features of human tumors, including hypoxia and drug resistance. The model offers researchers a more physiologically relevant platform for evaluating cancer therapeutics and investigating tumor biology.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-05-16

  Schwartz (2022) introduces an improved framework to distinguish drug-induced proliferative arrest from cell death in cancer in vitro assays, revealing that most anti-cancer agents induce both effects but at different rates and timing. This clarification enhances the reliability of preclinical drug testing and informs more precise experimental designs.

• Early Life Adversity Alters Innate Fear via Oxytocin Pathway

  2026-05-15

  This study establishes that early life adversity (ELA) in mice impairs visually evoked innate defensive behaviors by disrupting oxytocin signaling in the superior colliculus. The findings reveal a mechanistic link between early environmental stress, neural circuit modulation, and innate fear processing, providing a foundation for future intervention strategies.

• LL-37 Peptides Target MDR Acinetobacter baumannii and Biofil

  2026-05-15

  This study demonstrates that the human cathelicidin LL-37 and its fragments possess potent antimicrobial and antibiofilm activity against multidrug-resistant (MDR) Acinetobacter baumannii. The findings highlight the translational potential of LL-37-based strategies for combating difficult hospital-acquired infections.

583 records 12/39 page Previous Next First page 上5页 1112131415 下5页 Last page